查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2012629

皮膚癌診斷和治療市場：按治療方法、癌症類型、診斷方法和最終用戶分類－2026年至2032年全球市場預測

Skin Cancer Diagnostics & Therapeutics Market by Therapeutic Approach, Cancer Type, Diagnostic Type, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，皮膚癌診斷和治療市場價值將達到 92.2 億美元，到 2026 年將成長至 102.3 億美元，到 2032 年將達到 198.2 億美元，複合年成長率為 11.55%。

主要市場統計數據
基準年 2025 92.2億美元
預計年份：2026年 102.3億美元
預測年份 2032 198.2億美元
複合年成長率 (%) 11.55%

策略性介紹概述了綜合診斷和新興治療方法如何重新定義皮膚癌治療的臨床路徑和商業性重點。

診斷準確性與治療創新相結合，正在重塑皮膚癌的臨床治療路徑。近年來，分子診斷和先進影像技術的成熟，以及新一代免疫療法和標靶治療的出現，正在建構更整合的早期檢測、分層治療和長期患者管理方法。隨著臨床團隊和商業性相關人員適應這種融合趨勢，將診斷的準確性與治療方法方案結合的能力正成為一項關鍵優勢。

對診斷技術和治療突破領域融合的創新進行精闢的概述，這些創新正在重塑臨床實踐、支付方的期望以及相關人員的合作。

近年來，皮膚癌的檢測、鑑別和治療方式發生了變革性變化。尤其值得注意的是，免疫療法已從實驗性治療方案轉變為晚期皮膚癌治療的核心支柱，這促使人們重新評估生物標記策略和聯合治療。同時，標靶治療，特別是針對已明確致癌驅動基因的標靶治療，也取得了顯著進展，使得以往只能接受細胞毒性療法的患者亞群能夠得到更精準的治療。

對美國關稅在 2025 年的累積影響如何重塑各產業的供應鏈、籌資策略和成本結構進行冷靜分析。

政策和貿易決策正日益影響技術開發商和醫療保健供應商的業務運作和商業決策。美國宣布2025年加徵的關稅，其累積影響遠不止於進口零件和成品成本的即時上漲。這些政策措施正在推動供應鏈重組，製造商正加速供應商多元化和近岸外包，以降低關稅波動帶來的風險。因此，採購團隊和醫療設備製造商面臨原料成本飆升和漫長的認證流程，因為替代供應商需要經過審查和檢驗。

將治療方法、癌症亞型、診斷技術和最終用戶環境與策略商業化選擇聯繫起來的全面細分洞察。

一套精細的細分框架揭示了皮膚癌領域內臨床需求、技術成熟度和商業性機會的交匯點。在考慮治療方法時，臨床上已建立的治療方法（例如冷凍療法）與先進的免疫療法平台（包括癌症疫苗、查核點抑制劑和細胞激素療法）並存。同時，動態療法在某些表中仍然發揮作用，而標靶治療則專注於以BRAF和MEK抑制劑為基礎的分子標靶方法。這種治療方法的多樣性要求研發人員將作用機制與診斷精確度和患者選擇策略結合。

關鍵區域見解解釋了監管多樣性、支付方方案和醫療保健基礎設施如何塑造美洲、歐洲、中東、非洲和亞太地區的部署模式。

區域趨勢對創新皮膚癌療法的推廣、監管路徑、報銷環境以及臨床試驗參與者招募均有顯著影響。在美洲，大型臨床中心的集中分佈和活躍的保險公司環境，以及完善的報銷管道，推動了新治療方法和診斷方法的快速普及，儘管面臨複雜的採購流程和價格競爭等挑戰。而在歐洲、中東和非洲，監管環境的差異和支付體系的多樣性造成了複雜的准入路徑，需要針對特定區域制定證據包和彈性價格設定模式，才能有效滲透到各國的醫療保健體系中。

對競爭動態進行重點分析，展示合作關係、診斷和治療組合以及基於證據的差異化如何決定一家公司在該行業的定位。

該領域的競爭動態呈現出成熟臨床公司、新興生物技術創新者和專業診斷技術供應商並存的局面。成熟的製藥和醫療設備公司持續投資於產品生命週期管理和拓展適應症，而小規模的生物技術公司則致力於研發差異化的免疫療法和標靶治療，以應對分子層面定義的特定患者群體。診斷技術供應商則日益注重與數位病理學和人工智慧的整合，以提升病灶評估、影像解讀和工作流程效率。

為行業領導者提供切實可行的建議，以協調開發、供應鏈、證據生成和商業化，從而確保永續的競爭優勢。

領導企業需要採取果斷行動，將科學創新轉化為永續的商業性成功。首先，他們必須優先考慮將生物標記策略與臨床試驗設計緊密結合的合作開發路徑，儘早納入診斷標準，並確保證據的產生既能支持監管核准，又能向支付方提案價值。其次，他們必須投資於區域監管洞察和衛生經濟學能力，以創建符合關鍵地區支付方要求的客製化證據檔案。

透明的調查方法，用於產生可操作的策略見解，詳細說明相關人員訪談、文獻整合、監管審查和情境分析。

本研究整合了對臨床醫生、支付方和行業高管的訪談，並嚴格審查了同行評審文獻、監管申報文件和公開的臨床試驗註冊信息，從而構建了該領域的全面圖景。數據收集優先考慮來自皮膚科和腫瘤科專家、診斷實驗室主任和採購經理的直接見解，以確保結論是基於真實世界的實踐。分析方法包括對診斷方式進行橫斷面比較、繪製治療作用機製圖譜以及對商業性和監管影響進行情境分析，以識別策略轉折點。

簡潔的結論整合了臨床創新、營運挑戰和策略重點，以實現對患者的影響和商業性成功。

總而言之，在免疫療法、標靶治療和精準診斷技術的進步推動下，皮膚癌診斷和治療生態系統正在經歷一場積極的變革。這些進步正在建構更個人化的治療路徑，提升基於生物標記的患者篩選的重要性，並增強綜合診斷和治療策略的價值。同時，貿易政策的變化和區域監管差異等外部因素正在重塑營運重點，並影響商業化進程，這要求在整個產品生命週期中採取適應性策略。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 依治療方法分類的皮膚癌診斷和治療市場

  • 冷凍療法
  • 免疫療法
    • 癌症疫苗
    • 查核點抑制劑
    • 細胞激素療法
  • 動態療法
  • 標靶治療
    • BRAF抑制劑
    • MEK抑制劑

第9章：按癌症類型分類的皮膚癌診斷和治療市場

  • 基底細胞癌
  • 惡性黑色素瘤
  • 鱗狀細胞癌

第10章：按診斷類型分類的皮膚癌診斷和治療市場

  • 共聚焦顯微鏡
  • 皮膚鏡檢查
  • 診斷影像
    • 電腦斷層掃描
    • 磁振造影
    • 光學同調斷層掃描
    • 超音波
  • 分子診斷
  • 皮膚切片檢查

第11章 皮膚癌診斷與治療市場：依最終使用者分類

  • 門診手術中心
  • 皮膚科診所
  • 居家照護設施
  • 醫院
  • 癌症專科中心

第12章 皮膚癌診斷與治療市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章 皮膚癌診斷與治療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 皮膚癌診斷與治療市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國皮膚癌診斷與治療市場

第16章：中國皮膚癌診斷與治療市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • Bristol-Myers Squibb Company
  • Castle Biosciences, Inc.
  • DermTech, Inc.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • Genentech, Inc.
  • Illumina, Inc.
  • Iovance Biotherapeutics
  • Merck & Co., Inc.
  • Moderna, Inc.
  • Novartis AG
  • Pfizer Inc.
  • Qiagen NV
  • Regeneron Pharmaceuticals, Inc.
  • Sanofi SA
  • Siemens Healthineers AG
  • Sun Pharmaceutical Industries Ltd.
  • Thermo Fisher Scientific Inc.
Product Code: MRR-4342CA3266E1

The Skin Cancer Diagnostics & Therapeutics Market was valued at USD 9.22 billion in 2025 and is projected to grow to USD 10.23 billion in 2026, with a CAGR of 11.55%, reaching USD 19.82 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 9.22 billion
Estimated Year [2026] USD 10.23 billion
Forecast Year [2032] USD 19.82 billion
CAGR (%) 11.55%

A strategic introduction framing how integrated diagnostics and emerging therapeutic modalities are redefining clinical pathways and commercial priorities in skin cancer care

The intersection of diagnostic precision and therapeutic innovation is reshaping clinical pathways for skin cancer care. Recent years have seen the maturation of molecular diagnostics and advanced imaging modalities alongside a new generation of immunotherapies and targeted agents, creating a more integrated approach to early detection, stratified treatment, and longitudinal patient management. As clinical teams and commercial stakeholders adapt to this convergence, the ability to link diagnostic certainty with therapeutic selection has become a defining advantage.

Consequently, organizations that align R&D, regulatory strategy, and commercial planning around interoperable diagnostic-therapeutic ecosystems are better positioned to influence standards of care. At the same time, healthcare systems demand demonstrable improvements in outcomes and cost-effectiveness, pressuring developers to validate real-world utility through robust clinical evidence and health economics analyses. In this environment, clarity about technology differentiation, clinical workflow integration, and stakeholder incentives is essential for advancing innovation from bench to bedside.

Looking ahead, strategic choices in product design, partnerships, and market access will determine which technologies scale effectively. Companies that prioritize seamless clinical implementation, clinician education, and payer engagement will accelerate adoption and create durable competitive advantages in the evolving landscape of skin cancer management.

An incisive overview of the converging diagnostic innovations and therapeutic breakthroughs that are reshaping clinical practice, payer expectations, and stakeholder collaboration

The last several years have introduced transformative shifts that are recalibrating how skin cancer is detected, characterized, and treated. Most notably, immunotherapy has migrated from an experimental option to a central pillar for advanced disease, prompting a re-examination of biomarker strategies and combination regimens. Parallel advances in targeted therapy, especially agents focused on well-defined oncogenic drivers, have enabled precision approaches for patient subsets previously limited to cytotoxic regimens.

On the diagnostic front, noninvasive technologies and molecular assays are enhancing early detection and risk stratification, thereby creating more defined patient pathways and reducing diagnostic uncertainty. Imaging innovations and point-of-care modalities are likewise improving lesion characterization, enabling clinicians to triage cases with greater confidence and to select tailored interventions. These diagnostic improvements are influencing trial design, regulatory acceptance, and real-world uptake because they provide clearer endpoints and enable more efficient patient enrollment.

Concurrently, reimbursement dynamics and care delivery models are shifting toward value-based frameworks that reward demonstrable improvements in outcomes and patient experience. As a result, product developers must not only prove clinical efficacy but also articulate economic value across the continuum of care. Taken together, these shifts are accelerating convergence across previously discrete domains and creating new opportunities for cross-disciplinary collaboration and commercial differentiation.

A clear-eyed analysis of how the cumulative effects of United States tariffs in 2025 have reconfigured supply chains, procurement strategies, and cost structures across the sector

Policy and trade decisions are increasingly shaping the operational and commercial calculus for technology developers and healthcare providers. The announced United States tariffs for 2025 have produced cumulative effects that extend beyond immediate cost increases for imported components and finished devices. These policy measures have prompted supply chain reconfiguration, with manufacturers accelerating supplier diversification and nearshoring to mitigate exposure to tariff volatility. In turn, procurement teams and device manufacturers face higher input costs and longer qualification timelines as alternative suppliers are vetted and validated.

Clinically, the tariff-driven increases in the cost of diagnostic equipment components, consumables, and reagent imports have pressured pricing models and contributed to recalibrated capital expenditure plans within health systems. As institutions seek to preserve access to advanced imaging and diagnostics, they are balancing investments by prioritizing the highest-yield technologies and extending use cycles for capital assets. Additionally, biopharma and device companies have adjusted clinical trial budgets and timelines to account for incremental logistics and manufacturing expenses, potentially affecting program prioritization and partnership structures.

In response, organizations are adopting strategic measures such as local manufacturing partnerships, flexible pricing strategies, and enhanced inventory planning to maintain continuity of supply. Stakeholders that actively address tariff-induced constraints through procurement innovation and forward-looking commercial strategies will be better positioned to sustain product availability and protect margins under evolving trade conditions.

Comprehensive segmentation insights that connect therapeutic modalities, cancer subtypes, diagnostic technologies, and end-user settings to strategic commercialization choices

A nuanced segmentation framework illuminates where clinical need, technological maturity, and commercial opportunity intersect across the skin cancer landscape. When considering therapeutic approach, clinically established modalities such as cryotherapy coexist with advanced immunotherapy platforms that include cancer vaccines, checkpoint inhibitors, and cytokine therapies, while photodynamic therapy maintains a role in select superficial indications and targeted therapy focuses on molecular targets enabled by BRAF inhibitors and MEK inhibitors. This therapeutic diversity requires developers to align mechanism-of-action with diagnostic precision and patient selection strategies.

Evaluating cancer type reveals discrete clinical pathways and unmet needs when comparing basal cell carcinoma, melanoma, and squamous cell carcinoma, each with distinct biological behavior and treatment paradigms. For diagnostics, the spectrum spans confocal microscopy and dermoscopy for lesion assessment, through imaging modalities such as computed tomography, magnetic resonance imaging, optical coherence tomography, and ultrasound for staging and tumor mapping, to molecular diagnostics and skin biopsy for definitive characterization. These diagnostic choices have direct implications for trial enrollment criteria, regulatory evidence generation, and payer value assessments.

End-user segmentation further clarifies deployment pathways: ambulatory surgery centers, dermatology clinics, home care settings, hospitals, and specialty cancer centers differ in procedural volume, reimbursement frameworks, and operational readiness. Understanding how therapeutic and diagnostic offerings map to these care settings enables targeted commercialization plans, optimized training programs, and realistic adoption timelines based on individual site capabilities.

Key regional insights that explain how regulatory diversity, payer systems, and healthcare infrastructure shape adoption patterns across the Americas, Europe Middle East & Africa, and Asia-Pacific

Regional dynamics significantly influence technology adoption, regulatory pathways, reimbursement environments, and clinical trial recruitment for skin cancer innovations. In the Americas, a concentration of leading clinical centers and active payer environments fosters rapid adoption of novel therapies and diagnostics, supported by well-established reimbursement channels but challenged by complex procurement and competitive pricing pressures. Across Europe, Middle East & Africa, regulatory heterogeneity and diverse payer systems create a mosaic of access pathways, requiring localized evidence packages and flexible pricing models to achieve penetration in different national health systems.

In the Asia-Pacific region, strong investments in medical infrastructure, increasing public health focus on cancer screening, and growing domestic manufacturing capacity are driving uptake of both diagnostics and therapeutics. However, variations in clinical practice patterns and reimbursement mechanisms mean that market entry strategies must be highly tailored, often relying on regional clinical partnerships and localized health economic evidence. Taken together, these regional differences necessitate differentiated go-to-market approaches that account for regulatory timelines, clinical adoption drivers, and payer expectations in each geography.

Therefore, organizations must prioritize region-specific regulatory engagement, local evidence development, and strategic partnerships to translate technological advantage into sustained clinical and commercial impact across heterogeneous healthcare landscapes.

A focused assessment of competitive dynamics showing how alliances, diagnostic-therapeutic pairing, and evidence-driven differentiation define company positioning across the sector

Competitive dynamics in this sector reflect a mix of established clinical incumbents, emerging biotech innovators, and specialized diagnostic technology providers. Incumbent pharmaceutical and device companies continue to invest in lifecycle management and indication expansion, while smaller biotech firms advance differentiated immunotherapeutics and targeted agents that address niche molecularly defined populations. Diagnostic technology providers are increasingly focused on integration with digital pathology and artificial intelligence to enhance lesion assessment, image interpretation, and workflow efficiency.

Partnerships between therapeutic developers and diagnostic companies are accelerating companion diagnostic strategies and co-development programs that seek to align biomarker identification with therapeutic responsiveness. In parallel, service providers including contract manufacturers and clinical research organizations are adapting to the dual demands of biologic therapeutics and complex diagnostic reagents, offering specialized capabilities that enable faster time-to-market. Competitive advantage increasingly depends on the ability to demonstrate clinical utility, interoperability with clinical workflows, and compelling health economic value.

As a result, organizations that combine scientific excellence with robust clinical evidence frameworks, scalable manufacturing, and clear reimbursement strategies will be best positioned to secure favorable positioning in a crowded and rapidly evolving marketplace.

Actionable recommendations for industry leaders to align development, supply chain, evidence generation, and commercialization for sustained competitive advantage

Leaders in therapeutics and diagnostics must take decisive steps to convert scientific innovation into durable commercial success. First, prioritize co-development pathways that tightly couple biomarker strategies with clinical trial design, ensuring that diagnostic criteria are embedded early and that evidence generation supports both regulatory clearance and payer value narratives. Next, invest in regional regulatory intelligence and health economics capabilities to create tailored evidence dossiers that align with payer requirements across major geographies.

Operationally, diversify supply chains and explore nearshoring or dual-sourcing arrangements to limit exposure to trade-related disruptions and to preserve continuity of supply for critical reagents and device components. Commercial teams should develop clinician education programs and implementation toolkits that reduce adoption friction, including standardized workflows, training modules, and decision-support materials. Finally, pursue strategic partnerships-whether co-development, licensing, or distribution agreements-that extend market reach while sharing development risk and enabling rapid scale-up.

Taken together, these actions will help organizations de-risk development pathways, accelerate adoption, and create defensible differentiation in an environment where clinical evidence, operational resilience, and payer alignment determine long-term success.

A transparent research methodology detailing stakeholder interviews, literature synthesis, regulatory review, and scenario analysis used to produce actionable strategic insights

This research synthesizes primary interviews with clinicians, payers, and industry executives alongside a rigorous review of peer-reviewed literature, regulatory filings, and public clinical trial registries to construct an integrated view of the field. Data collection prioritized direct insights from specialty clinicians in dermatology and oncology, diagnostic laboratory directors, and procurement leaders to ground conclusions in operational realities. Analytical approaches included cross-sectional comparison of diagnostic modalities, therapy mechanism-of-action mapping, and scenario analysis of trade and regulatory impacts to illuminate strategic inflection points.

Where applicable, technology assessments evaluated clinical utility, integration complexity, and readiness for scaling within typical care pathways. Regulatory and reimbursement analyses relied on recent guidance documents and payer determinations to identify common evidence expectations and coverage barriers. Finally, competitive and partnership landscapes were assessed using observable deal activity, public company disclosures, and industry interviews to surface patterns in collaboration and go-to-market execution.

This mixed-methods approach ensures that conclusions reflect both qualitative stakeholder perspectives and objective, verifiable sources, providing a practical foundation for strategic decision-making without reliance on proprietary or proprietary dataset extrapolations.

A concise conclusion that synthesizes clinical innovation, operational challenges, and strategic priorities for realizing patient impact and commercial success

In sum, the skin cancer diagnostics and therapeutics ecosystem is in a period of constructive disruption driven by advances in immunotherapy, targeted agents, and diagnostic precision. These developments are creating more personalized care pathways, amplifying the importance of biomarker-driven patient selection, and increasing the value of integrated diagnostic-therapeutic strategies. At the same time, external factors such as trade policy shifts and regional regulatory diversity are reshaping operational priorities and influencing commercial timelines, requiring adaptive strategies across the product lifecycle.

Organizations that combine clinical rigor with operational resilience and market-facing evidence will be well placed to translate innovation into impact. Emphasizing early diagnostic-therapeutic alignment, robust health economic evidence, and flexible supply chain arrangements will reduce adoption friction and sustain access despite external headwinds. Ultimately, success will depend on the ability to move beyond individual product performance and to demonstrate measurable improvements in patient outcomes, care efficiency, and affordability across the care continuum.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Skin Cancer Diagnostics & Therapeutics Market, by Therapeutic Approach

  • 8.1. Cryotherapy
  • 8.2. Immunotherapy
    • 8.2.1. Cancer Vaccines
    • 8.2.2. Checkpoint Inhibitors
    • 8.2.3. Cytokine Therapy
  • 8.3. Photodynamic Therapy
  • 8.4. Targeted Therapy
    • 8.4.1. BRAF Inhibitors
    • 8.4.2. MEK Inhibitors

9. Skin Cancer Diagnostics & Therapeutics Market, by Cancer Type

  • 9.1. Basal Cell Carcinoma
  • 9.2. Melanoma
  • 9.3. Squamous Cell Carcinoma

10. Skin Cancer Diagnostics & Therapeutics Market, by Diagnostic Type

  • 10.1. Confocal Microscopy
  • 10.2. Dermoscopy
  • 10.3. Imaging
    • 10.3.1. Computed Tomography
    • 10.3.2. Magnetic Resonance Imaging
    • 10.3.3. Optical Coherence Tomography
    • 10.3.4. Ultrasound
  • 10.4. Molecular Diagnostics
  • 10.5. Skin Biopsy

11. Skin Cancer Diagnostics & Therapeutics Market, by End User

  • 11.1. Ambulatory Surgery Centers
  • 11.2. Dermatology Clinics
  • 11.3. Home Care Settings
  • 11.4. Hospitals
  • 11.5. Specialty Cancer Centers

12. Skin Cancer Diagnostics & Therapeutics Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Skin Cancer Diagnostics & Therapeutics Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Skin Cancer Diagnostics & Therapeutics Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Skin Cancer Diagnostics & Therapeutics Market

16. China Skin Cancer Diagnostics & Therapeutics Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Abbott Laboratories
  • 17.6. AbbVie Inc.
  • 17.7. Amgen Inc.
  • 17.8. AstraZeneca PLC
  • 17.9. Bristol-Myers Squibb Company
  • 17.10. Castle Biosciences, Inc.
  • 17.11. DermTech, Inc.
  • 17.12. Eli Lilly and Company
  • 17.13. F. Hoffmann-La Roche Ltd
  • 17.14. Genentech, Inc.
  • 17.15. Illumina, Inc.
  • 17.16. Iovance Biotherapeutics
  • 17.17. Merck & Co., Inc.
  • 17.18. Moderna, Inc.
  • 17.19. Novartis AG
  • 17.20. Pfizer Inc.
  • 17.21. Qiagen N.V.
  • 17.22. Regeneron Pharmaceuticals, Inc.
  • 17.23. Sanofi S.A.
  • 17.24. Siemens Healthineers AG
  • 17.25. Sun Pharmaceutical Industries Ltd.
  • 17.26. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY CRYOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY CRYOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY CRYOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY CANCER VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY CANCER VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY CANCER VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY CYTOKINE THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY CYTOKINE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY CYTOKINE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PHOTODYNAMIC THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PHOTODYNAMIC THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PHOTODYNAMIC THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY BRAF INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY BRAF INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY BRAF INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY MEK INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY MEK INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY MEK INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY BASAL CELL CARCINOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY BASAL CELL CARCINOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY BASAL CELL CARCINOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY MELANOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY MELANOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY MELANOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SQUAMOUS CELL CARCINOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SQUAMOUS CELL CARCINOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SQUAMOUS CELL CARCINOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY CONFOCAL MICROSCOPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY CONFOCAL MICROSCOPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY CONFOCAL MICROSCOPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DERMOSCOPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DERMOSCOPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DERMOSCOPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY OPTICAL COHERENCE TOMOGRAPHY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY OPTICAL COHERENCE TOMOGRAPHY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY OPTICAL COHERENCE TOMOGRAPHY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY ULTRASOUND, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY ULTRASOUND, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY ULTRASOUND, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SKIN BIOPSY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SKIN BIOPSY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SKIN BIOPSY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DERMATOLOGY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DERMATOLOGY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DERMATOLOGY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SPECIALTY CANCER CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SPECIALTY CANCER CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SPECIALTY CANCER CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. AMERICAS SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 89. AMERICAS SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2032 (USD MILLION)
  • TABLE 90. AMERICAS SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 91. AMERICAS SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 92. AMERICAS SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 93. AMERICAS SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2032 (USD MILLION)
  • TABLE 94. AMERICAS SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 95. AMERICAS SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 96. NORTH AMERICA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2032 (USD MILLION)
  • TABLE 98. NORTH AMERICA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 99. NORTH AMERICA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 100. NORTH AMERICA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 101. NORTH AMERICA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2032 (USD MILLION)
  • TABLE 102. NORTH AMERICA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 103. NORTH AMERICA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 104. LATIN AMERICA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. LATIN AMERICA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2032 (USD MILLION)
  • TABLE 106. LATIN AMERICA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 107. LATIN AMERICA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 108. LATIN AMERICA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 109. LATIN AMERICA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. LATIN AMERICA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 111. LATIN AMERICA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE, MIDDLE EAST & AFRICA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE, MIDDLE EAST & AFRICA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE, MIDDLE EAST & AFRICA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE, MIDDLE EAST & AFRICA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE, MIDDLE EAST & AFRICA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE, MIDDLE EAST & AFRICA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE, MIDDLE EAST & AFRICA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE, MIDDLE EAST & AFRICA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 128. MIDDLE EAST SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. MIDDLE EAST SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2032 (USD MILLION)
  • TABLE 130. MIDDLE EAST SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 131. MIDDLE EAST SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 132. MIDDLE EAST SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 133. MIDDLE EAST SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. MIDDLE EAST SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 135. MIDDLE EAST SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 136. AFRICA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 137. AFRICA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2032 (USD MILLION)
  • TABLE 138. AFRICA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 139. AFRICA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 140. AFRICA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 141. AFRICA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2032 (USD MILLION)
  • TABLE 142. AFRICA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 143. AFRICA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 144. ASIA-PACIFIC SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. ASIA-PACIFIC SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2032 (USD MILLION)
  • TABLE 146. ASIA-PACIFIC SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 147. ASIA-PACIFIC SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 148. ASIA-PACIFIC SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 149. ASIA-PACIFIC SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2032 (USD MILLION)
  • TABLE 150. ASIA-PACIFIC SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 151. ASIA-PACIFIC SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 153. ASEAN SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. ASEAN SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2032 (USD MILLION)
  • TABLE 155. ASEAN SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 156. ASEAN SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 157. ASEAN SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 158. ASEAN SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2032 (USD MILLION)
  • TABLE 159. ASEAN SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 160. ASEAN SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 161. GCC SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 162. GCC SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2032 (USD MILLION)
  • TABLE 163. GCC SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 164. GCC SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 165. GCC SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 166. GCC SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2032 (USD MILLION)
  • TABLE 167. GCC SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 168. GCC SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPEAN UNION SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPEAN UNION SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPEAN UNION SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPEAN UNION SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPEAN UNION SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPEAN UNION SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPEAN UNION SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPEAN UNION SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 177. BRICS SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 178. BRICS SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2032 (USD MILLION)
  • TABLE 179. BRICS SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 180. BRICS SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 181. BRICS SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 182. BRICS SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2032 (USD MILLION)
  • TABLE 183. BRICS SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 184. BRICS SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 185. G7 SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 186. G7 SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2032 (USD MILLION)
  • TABLE 187. G7 SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 188. G7 SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 189. G7 SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 190. G7 SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. G7 SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 192. G7 SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 193. NATO SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 194. NATO SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2032 (USD MILLION)
  • TABLE 195. NATO SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 196. NATO SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 197. NATO SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 198. NATO SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2032 (USD MILLION)
  • TABLE 199. NATO SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 200. NATO SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 201. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 202. UNITED STATES SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 203. UNITED STATES SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2032 (USD MILLION)
  • TABLE 204. UNITED STATES SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 205. UNITED STATES SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 206. UNITED STATES SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 207. UNITED STATES SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2032 (USD MILLION)
  • TABLE 208. UNITED STATES SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 209. UNITED STATES SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 210. CHINA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 211. CHINA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2032 (USD MILLION)
  • TABLE 212. CHINA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 213. CHINA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 214. CHINA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 215. CHINA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2032 (USD MILLION)
  • TABLE 216. CHINA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 217. CHINA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)